LBL-007

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Esophageal Squamous Cell CarcinomaAdvanced MalignanciesMalignant TumorsAdvanced MelanomaUnresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal Cancer

103 competitors in Esophageal Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

1

Taxol

Teva

Phase 3

332

Beyfortus

BeiGene

Phase 3

213

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

344

Camptosar

Pfizer

Phase 3

115

Keytruda

Merck & Co.

Phase 3

86

Abraxane

Bristol-Myers Squibb

Phase 3

47

Tuoyi

CCoherus Oncology, Inc.

Phase 3

148

Opdivo

Bristol-Myers Squibb

Phase 3

39

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

910

Taxotere

AAvyxa

Phase 3

8Show 40 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Active, not recruiting·BeiGene·Phase 2·NCT06010303·118 enrolled

Malignant Tumors1 trial

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Recruiting·NNanjing Leads Biolabs Co.,Ltd·Phase 1/2·NCT05516914·490 enrolled

Advanced Malignant Tumors1 trial

A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors

Completed·NNanjing Leads Biolabs Co.,Ltd·Phase 1/2·NCT05102006·80 enrolled

Advanced Malignancies1 trial

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Enrolling by invitation·BBeOne Medicines·Phase 3·NCT04164199·430 enrolled

Advanced Solid Tumors1 trial

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Completed·BeiGene·Phase 1/2·NCT03744468·114 enrolled

5 more indications

Melanoma1 trial

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

Completed·NNanjing Leads Biolabs Co.,Ltd·Phase 1·NCT04640545·79 enrolled

Non-Small Cell Lung Cancer1 trial

Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Completed·BeiGene·Phase 2·NCT05635708·418 enrolled

Advanced Melanoma1 trial

An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.

Recruiting·NNanjing Leads Biolabs Co.,Ltd·Preclinical·NCT07099430·280 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Completed·BeiGene·Phase 2·NCT05909904·160 enrolled

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer1 trial

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Active, not recruiting·BeiGene·Preclinical·NCT05609370·113 enrolled

Details

Drug Info

Related News